WHO Drug Information Vol. 14, No. 4, 2000
(2000; 78 pages) View the PDF document
Table of Contents
Open this folder and view contentsGeneral Policy Issues
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters
View the documentEtanercept: serious haematological reactions
View the documentInfliximab: safety restrictions
View the documentPhenylpropanolamine withdrawn from drug products
View the documentLabelling revision for phenylpropanolamine
View the documentPhenylpropanolamine advisory to consumers
View the documentPhenylpropanolamine: strengthening of patient information
View the documentLevacetylmethadol and cardiac disorders
View the documentBovine-derived materials and vaccines: US recommendations
View the documentProducts containing human albumin
View the documentStavudine and didanosine: pregnancy advisory
View the documentMethysergide and cardiac valvulopathy
View the documentGreater control for cisapride
View the documentNew combination drug for HIV
View the documentTacrolimus for atopic dermatitis
View the documentLetrozole approved for advanced breast cancer
View the documentAlosetron withdrawn
View the documentBasiliximab: hypersensitivity reactions
View the documentBudipine: cardiac reactions
View the documentCapecitabine: revised data sheet
View the documentBenzathine penicillin: fatal mega-unit injections
View the documentDisulfiram: hepatic reactions
View the documentIsoniazid and rifampicin: severe skin reactions
View the documentOmeprazole-induced interstitial nephritis
View the documentOzagrel sodium: kidney function disorder
View the documentDrug information to the public
View the documentNorthern hemisphere influenza vaccine composition
View the documentATC/DDD Classification (final)
View the documentATC/DDD Classification (temporary)
Open this folder and view contentsHerbal Medicines
Open this folder and view contentsPublications and Sources of Information
 

Isoniazid and rifampicin: severe skin reactions

Zimbabwe - The Medicines Control Authority has recently received four adverse reaction reports of "burn-like lesions on the whole body and mucosal ulcerations" associated with isoniazid and rifampicin. None of the four patients were taking concomitant medicines. All patients recovered.

It was noted from records at the WHO Collaborating Centre for International Drug Monitoring that since 1993 the Authority had received seven reports of skin reactions (rash, pruritus) associated with rifampicin and isoniazid. Five of the seven reports indicated that the patients were also taking ethambutol and pyrazinamide.

Reference: Drug Information Bulletin, Vol. 4, No. 2, June 2000.

to previous section to next section
 

Last updated: May 3, 2013